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Development and validation of a LC-MS/MS method for the quantification of 52 
the checkpoint kinase 1 (CHK1) inhibitor SRA737 in human plasma 53 
 54 
Abstract 55 
Background: SRA737 is an orally active small molecule inhibitor of Checkpoint kinase 1 being 56 
investigated in an oncology setting. A HPLC-MS/MS method for quantifying plasma 57 
concentrations of SRA737 was validated. 58 
Methods & results: Sample preparation involved protein precipitation with acetonitrile 59 
following addition of 13C15N deuterated SRA737 as internal standard. A rapid and selective 60 
method was fully validated across a range of 5-20,000 ng/mL, exhibiting good sensitivity, 61 
overall precision (expressed as CV) ≤8.0% and accuracy 96-102%. Consistently high recovery 62 
was observed, with no matrix effect and a lower limit of quantitation of 5 ng/mL.  63 
Conclusion: A novel method for analysing SRA737 in human plasma has been validated and is 64 
now being utilised for quantification of SRA737 in a phase I trial.  65 
 66 
Keywords: CCT245737, SRA737, CHK1, LC-MS/MS, validation study, pharmacokinetics, 67 
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Introduction 70 
In an oncology setting the use of chemotherapy or radiotherapy is frequently associated with 71 
DNA damage [1]. In response to DNA damage, cells activate the DNA damage response (DDR), 72 
involving multiple signalling pathways such as cell cycle checkpoints, DNA repair, 73 
transcriptional programs and apoptosis. Cells maintain genomic integrity via the DNA damage 74 
response (DDR) which is critical for survival and proliferation.  Intrinsic genomic instability and 75 
an over-reliance on the DDR machinery is a hallmark feature of tumour development 76 
prompting the development of agents targeting DDR signalling pathways, particularly 77 
checkpoint kinase 1 (CHK1), which plays a key role in the DNA-damage checkpoint signal 78 
transduction pathway [2]. CHK1 has been shown to play a role in the disruption or halting of 79 
DNA replication to facilitate DNA repair following treatment with a variety of 80 
chemotherapeutics in mammalian cells [3, 4]. CHK1 inhibitors are predicted to prevent cells 81 
entering cell cycle arrest, thereby enhancing the activity of genotoxic agents such as 82 
gemcitabine and cisplatin. Chk1 inhibitors are also predicted to demonstrate synthetic 83 
lethality as monotherapy in tumours with certain genetic profiles. 84 
SRA737 (formerly known as CCT245737) is an orally active small molecule inhibitor of CHK1 85 
discovered at the Cancer Therapeutics Unit, Institute of Cancer Research, and developed for 86 
use in an oncology setting [5]. Inhibition of CHK1 function by SRA737 can result in substantial 87 
increases in the sensitivity of tumour cells to a variety of anticancer drugs [6, 7]. In this 88 
respect, SRA737 was shown to improve gemcitabine and SN38 antitumor activity without 89 
increasing toxicity in a human tumour xenograft model [7]. Following the generation of 90 
promising preclinical data, SRA737 is currently being tested in a Phase I clinical trial setting. 91 
To support the Phase I study of SRA737, a robust method for the quantification of SRA737 in 92 
human plasma is required for the generation of pharmacokinetic data. Thus far, no validated 93 
method for the quantification of SRA737 has been published. The current work describes the 94 
development and validation of a high performance liquid chromatography tandem mass 95 
spectrometry (LC–MS/MS) assay for the quantification of SRA737 in human plasma. The assay 96 
has been validated according to European Medicines Agency (EMA) and US Food and Drug 97 
Administration (FDA) guidelines for bioanalytical method validation [8, 9] and successfully 98 
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applied to support a pharmacokinetic study in advanced cancer patients in a Phase I clinical 99 
trial setting. 100 
 101 
  102 
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Experimental 103 
Standards & chemicals 104 
Analytical standards of SRA737 (MW 379.34 g/mol) and labelled SRA737 (13C15N deuterated 105 
SRA737; MW 383.35 g/mol) were provided by Cancer Research UK (Figure 1). HPLC grade 106 
acetonitrile, acetic acid and ammonium hydroxide were purchased from Fisher Scientific 107 
(Leics, UK). Control human plasma with sodium citrate, used to prepare daily standard 108 
calibration curves and quality control samples (QCs), was obtained from the Blood 109 
Transfusion Centre (Newcastle, UK). 110 
 111 
Standard solutions 112 
Two separate stock solutions of SRA737 for standards and QCs were prepared in 113 
dimethylformamide (DMF) at a concentration of 1 mg/mL. A stock solution of 13C15N 114 
deuterated SRA737 (Internal Standard; IS) was prepared at 1 mg/mL in DMF. Stock solutions 115 
were diluted serially in DMF to obtain working solutions, with final SRA737 concentrations of 116 
0.4, 1, 2, 20, 100, 200 and 400 µg/mL for standards and 0.6, 60 and 300 µg/mL for working 117 
solutions of QCs. These solutions were used to prepare calibration curve standards and QC 118 
samples in control human plasma. The IS working solution was prepared at a concentration 119 
of 1 μg/mL by diluting the stock solution with DMF. All solutions were stored at -20 °C prior 120 
to use. 121 
 122 
A ten-point calibration curve was utilised, with standard calibration samples prepared by 123 
adding 10 μL of the working standard solutions to plasma (190 μL), to produce final SRA737 124 
concentrations of 5, 10, 20, 50, 100, 150, 1000, 5000, 10000 and 20000 ng/mL. Each run 125 
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included a blank sample (plasma control processed without IS) and a zero blank sample 126 
(plasma control processed with IS). The QC samples were prepared by adding 10 μL of each 127 
working QC solution to human plasma control (190 μL) to obtain SRA737 concentrations of 128 
30, 3000 and 15000 ng/mL. 129 
 130 
Processing samples 131 
Plasma aliquots (20 µL) from study samples, standards or QC samples were vortex mixed 132 
with 10 µL (10 ng) of IS working solution and 100 µL of acetonitrile and samples were 133 
centrifuged at 4000 g for 5 minutes at room temperature. The supernatant obtained (100 134 
µL) was transferred to an Eppendorf tube and 100 µL of mobile phase A was added. 135 
Following vortex mixing, samples were transferred to autosampler vials and 3 µL volumes 136 
were routinely injected onto the HPLC-MS/MS system. 137 
 138 
Chromatography conditions 139 
A Prominence series HPLC system was utilised, consisting of a SIL-20AC XR autosampler, two 140 
LC-20AD XR pumps, a CBM-20A communications bus module and a CTO-20AC column oven 141 
(Shimadzu, Milton Keynes, Buckinghamshire, UK). A Phenomenex Kinetex C18 column (2.6 142 
µm, 50.0 x 4.6 mm) with a Phenomenex Security guard containing a C18 cartridge (4 x 2mm) 143 
was utilised for sample separation. Mobile phase A (MP A) consisted of 10 mM ammonium 144 
acetate + 0.5% ammonia (v/v) and MP B was acetonitrile. The HPLC system was set at a 145 
constant flow rate of 0.5 mL/min and run under gradient conditions: step 1 - 95% MP A for 1 146 
min; step 2 - 95% MP A to 5% over 3 min; step 3 - constant for 1 min; step 4 - 5% MP A to 147 
initial conditions over 1 min; step 5 - reconditioning for 4 min. 148 
 149 
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Mass spectrometry conditions 150 
An API 4000 triple quadrupole mass spectrometer from SCIEX (Foster City, CA, USA) was 151 
utilised in the current assay. MS parameters were optimised through the infusion of standard 152 
solutions (10 ng/mL) of SRA737 and IS at a flow rate of 0.5 mL/min. Positive ion mode was 153 
used to obtain the mass spectra (MS1) and the product ion spectra (MS2). Fragment selection 154 
during compound tuning was based on an initial fragmentation screen which produced four 155 
prominent fragments. These four fragments were further optimised for collision energy and 156 
collision cell exit potential and the best three selected for flow injection analysis and 157 
background testing. After testing in blank matrix under final chromatographic conditions, the 158 
best performing fragment by signal-to-noise comparison was chosen as the final transition. 159 
The instrument incorporated a Turbo Ion Spray source operated at 650°C, with voltage of 160 
5500 V. Biological samples were analysed with electrospray ionization (ESI), using zero air as 161 
the nebulizer gas (206.8 kPa) and as heater gas (482.6 kPa). Nitrogen was employed as curtain 162 
gas (206.8 kPa) and as collision gas at 34.5 kPa (CAD). The declustering potential (DP) was 163 
optimized and set to 71V for SRA737 and 61V for the 13C15N deuterated SRA737. 164 
Quantification was carried out in Selected Reaction Monitoring (SRM) mode following the 165 
transitions m/z 379.872 → 360.200 for SRA737 and m/z 384.086 → 324.200 for the IS. Data 166 
processing was carried out with Analyst 1.6.2 software package (SCIEX). 167 
 168 
Method validation 169 
Validation of the method was carried out according to EMA and FDA bioanalytical method 170 
validation guidance documents [8, 9]. Parameters validated included selectivity, 171 
anticoagulant comparison, matrix effect, recovery, lower limit of quantification (LLOQ), 172 
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linearity and range, dilutional integrity, carry-over effect, intra/inter-assay precision, accuracy 173 
and stability. 174 
 175 
Selectivity 176 
The selectivity of the method was assessed by analysing 6 independent sources of blank 177 
plasma. Any response with similar retention time to the analyte was required to be ≤ 20% of 178 
the response for the lowest concentration included in the standard curve. Any response with 179 
a similar retention time to the IS was required to be ≤ 5% of the response for the IS peak [8, 180 
9]. Experiments to investigate the interference of potentially co-administered drugs were not 181 
carried out as part of the assay method validation. 182 
 183 
Anticoagulant comparison 184 
The potential effects of different anticoagulants were determined by analysing 3 replicates at 185 
LQC and HQC concentrations of SRA737, which were prepared using blank plasma obtained 186 
through the use of 3 different anticoagulants: sodium citrate, potassium EDTA and lithium 187 
heparin. The coefficient of variation (CV) was required to be within 15% and accuracy within 188 
85-115% [8, 9]. 189 
 190 
Matrix effect 191 
Six independent sources of blank matrix for SRA737 at low and high QC concentrations and 192 
for the IS were utilised to calculate the matrix factor (MF) for each analyte, i.e. the ratio of 193 
the peak area of the analyte added to a pre-extracted sample to the peak area of an equal 194 
amount of analyte in solvent. The IS normalised MF was calculated by dividing the MF of 195 
SRA737 by the MF of IS. The CV of the IS-normalised MF was required to be within 15% [8, 9]. 196 
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 197 
Recovery 198 
Percentage extraction data were obtained using 3 QC concentrations (30, 3000 and 15000 199 
ng/mL) for SRA737 and at 500 ng/mL for the IS in plasma samples processed in triplicate. The 200 
peak area of SRA737 extracted from plasma samples was compared to the peak area in 201 
absence of matrix (true concentration of the analyte in solvent) to calculate the absolute 202 
recovery. The CV was required to be within 15% [8, 9]. 203 
 204 
Limit of quantification 205 
The LLOQ for the assay was defined as the concentration of the lowest standard with precision  206 
 20% and accuracy within 80-120% of the nominal value, with a signal-to-noise ratio ≥10. 207 
The defined LLOQ was assessed by preparing five plasma samples with SRA737 at a final 208 
concentration of 5.0 ng/mL, with the experiment repeated on 4 separate days [8, 9]. 209 
 210 
Linearity and Range 211 
Calibration curve linearity was investigated over seven working days, with the linear range 212 
determined over one working day through the preparation of samples <50% of the lowest 213 
concentration included in the standard curve and >150% of the upper limit of quantification 214 
(ULOQ). The ratio of the HPLC-MS/MS peak area for SRA737 to IS was calculated for each 215 
standard concentration and plotted against the nominal concentration of drug in the sample. 216 
Standard curve linearity was assessed by regression analysis and goodness of fit using 217 
Pearson’s determination coefficient R2 and through comparison of true and back-calculated 218 
concentrations of calibration standards. Back-calculated values were required to be within 219 
85-115% of the theoretical concentration (80-120% at the lowest concentration included in 220 
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the standard curve), and at least 75% of the standards were required to meet these criteria, 221 
including the lowest and the highest calibrators [8, 9]. 222 
 223 
Dilution integrity and carryover 224 
A 50 µg/mL solution of SRA737 was made in plasma and diluted 1 in 10 with control plasma 225 
to generate a 5000 ng/mL standard. Samples were prepared in 5 replicates. Accuracy and 226 
precision were required to be within ±15% [8]. Carryover of SRA737 and IS were evaluated by 227 
placing a blank sample directly after the highest calibration standard. Carryover sample 228 
analyte response was required to be ≤20% of the response observed for the lowest 229 
concentration on the standard curve. The IS response in the carryover sample was required 230 
to be ≤5% of the response for the control matrix + IS [8, 9]. 231 
 232 
Intra/Inter-assay precision and accuracy 233 
Intra-day precision and accuracy were investigated using five replicates per QC concentration, 234 
with data from four separate experiments carried out on different days generated to assess 235 
inter-day precision and accuracy. The precision of the method at each concentration was 236 
reported as the CV value, expressing the standard deviation as a percentage of the mean 237 
calculated concentration; accuracy was determined by expressing mean calculated 238 
concentrations as a percentage of the nominal concentration. Concentrations determined for 239 
QC samples in each run were required to be within 15% of the nominal value, with the 240 
exception of the LLOQ which should be within 20% [8, 9]. 241 
 242 
Stability 243 
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SRA737 stability in plasma was assessed by analysing low and high QC samples in triplicate 244 
following storage under various different conditions. Short-term stability was investigated 245 
using QC samples both unextracted and extracted (autosampler stability) from the plasma 246 
matrix after 7 days storage at 4°C, with bench-top stability at room temperature calculated 247 
over 4 h. Freeze–thaw stability was determined for three cycles over a range of -20°C and 248 
room temperature. Long-term stability was investigated using QC samples stored for 8 249 
months at -20°C. SRA737 QC samples were analysed against a calibration curve generated 250 
from freshly spiked standards, with the concentrations determined compared to the nominal 251 
concentrations. The mean obtained QC concentration was required to be within ±15% of the 252 
nominal concentration [8, 9]. 253 
 254 
Application of method to clinical sample analysis 255 
The method was used to quantify SRA737 plasma concentrations in a patient with advanced 256 
cancer treated on the ongoing Phase I clinical trial of SRA737 administered as single agent 257 
monotherapy (EudraCT number 2015-004486-86). Blood samples for pharmacokinetic 258 
analysis were obtained prior to administration of a single oral dose of 40 mg SRA737 and at 259 
0.5, 1, 2, 4, 6, 8, 12 and 24 h post-administration. Blood samples (2 mL) were collected into 260 
EDTA tubes and centrifuged at 1200 g for 5 min at 4°C. Plasma was separated and frozen at -261 
20°C prior to analysis as described above. 262 
 263 
  264 
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Results & discussion 265 
HPLC-MS/MS 266 
Using an ESI source in positive ion mode, SRA737 formed mainly a molecular ion M+ at m/z 267 
379.872, while 13C15N deuterated SRA737 (IS) formed a protonated molecule [M+H]+ at m/z 268 
384.086. These precursor ions passed through the first quadrupole into the collision cell and 269 
the collision energy (CE) was optimized to obtain a high signal for the product ions generated. 270 
After fragmentation, the characteristic products were monitored in the third quadrupole at 271 
m/z 320.2 (35 eV), 360.2 (25 eV) and 255.0 (39 eV) for SRA737 and at m/z 324.2 (33 eV) and 272 
259.2 (39 eV) for the IS. The fragmentation patterns are presented in Figure 2; SRA737 and IS 273 
were quantified using the transitions m/z 379.872 → 360.200 (Figure 2A) and m/z 384.086 → 274 
324.200 (Figure 2B). Figure 3 represents typical SRM chromatograms, using the same SRA737 275 
and IS transitions as above. Figure 3A shows an extracted blank plasma sample; Figure 3B 276 
shows an extracted blank plasma sample with IS added; Figure 3C represents an extracted 277 
plasma sample at the LLOQ (5 ng/mL) with IS. The elution of the analytes was efficient and 278 
selective, SRA737 and IS being eluted at ∼4 min. No interfering peaks were observed at these 279 
retention times and the peaks were completely resolved from the plasma matrix with good 280 
peak shape observed. The specificity of the method was confirmed by analysing six 281 
independent sources of blank human plasma. 282 
 283 
Method validation 284 
Selectivity 285 
Selectivity was evaluated on 6 different batches of human plasma, including haemolysed 286 
plasma. The method shown to be selective with an absence of interfering components. 287 
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Response with similar retention time was <7 % of the LOQ and <1 % for the IS in six batches 288 
of plasma evaluated. 289 
 290 
Anticoagulant comparison and matrix effect 291 
The potential effect of different anticoagulants was determined by analysing 3 replicates at 292 
LQC and HQC concentrations of SRA737, prepared using blank plasma obtained through the 293 
use of potassium EDTA and lithium heparin, as compared to control citrate plasma. No effect 294 
of different anticoagulants was observed, with a calculated CV ≤ 4.8 % and accuracy within 295 
the range 97-100 %, indicating that plasma obtained from blood samples collected with any 296 
of these commonly used anticoagulants could be utilised to generate accurate results. The 297 
matrix effect was evaluated on 6 different batches of human plasma, including haemolysed 298 
plasma at LQC and HQC concentrations. There were no significant differences between the 299 
six lots evaluated by assessment of IS-corrected matrix factor, with calculated values of 1.02 300 
± 0.03 for LQC (CV 3.4%) and 0.96 ± 0.02 for HQC (CV 2.1 %). 301 
 302 
Recovery and limit of quantification 303 
Recovery was determined in triplicate using three QC concentrations through comparison of 304 
peak areas of spiked plasma samples following extraction, with peak areas obtained from 305 
direct injection of SRA737 standards in mobile phase. Recovery percentages for SRA737 were 306 
114%, 95.7% and 93.7% at concentrations of 30, 3000 and 15000 ng/mL, respectively, with a 307 
recovery of 102% observed for the IS. There were no significant variations (1.8-8.3%) for the 308 
peak areas of SRA737 and IS and all data generated were in the anticipated and acceptable 309 
range. The LLOQ concentration in plasma was defined to be 5.0 ng/mL, with precision and 310 
accuracy of 5.4% and 102.9%, respectively determined by preparing five plasma samples with 311 
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CCT245737 at a final concentration of 5.0 ng/mL, with the experiment repeated on 4 separate 312 
days, at this concentration of SRA737 (see Table 2). For LLOQ and LQC concentrations the 313 
volume of injection was increased from 3 µL to 10 µL. All results are expressed as a ratio of 314 
the peak area of SRA737 to IS and therefore the overall data generated are unaffected by 315 
sample volume. 316 
 317 
Linearity and Range 318 
Linearity was investigated over ten concentrations of SRA737 (range 5-20000 ng/mL), with a 319 
linear correlation of ≥0.997 calculated from 7 separate experiments. The calibration curve 320 
was typically described by the linear equation y = 1.75x + 0.003, with 1/y2 weighting. The 321 
weighting of 1/y2 gave the best linear response, with consistent % relative error values across 322 
the standard curve concentration range and correlation coefficients with excellent 323 
reproducibility. Table 1 shows linearity and range data over a SRA737 concentration range of 324 
5-20000 ng/mL. 325 
 326 
Dilution integrity and carryover 327 
A 50 µg/mL spiked sample was generated in plasma and diluted 1 in 10 in plasma to a 328 
concentration of 5000 ng/mL, with an accuracy of 91% observed. Carry-over effects were 329 
negated by injecting 2 mobile phase samples and 2 extracted blank plasma samples after the 330 
injection of ULOQ samples or high concentration samples. 331 
 332 
Intra/Inter-assay precision, accuracy and stability 333 
The intra-assay study showed precision ≤5.6 % and accuracy ranging from 96.5 - 100 % (n = 334 
5). The inter-assay study over four days showed precision ≤7.9 % and accuracy 96.5 - 106 % 335 
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as shown in Table 2. SRA737 stability in plasma was determined by analysing triplicate QC 336 
samples at low and high concentrations. SRA737 was stable in plasma for at least 4 h at room 337 
temperature and for 7 days at 4°C both before and after drug extraction. SRA737 was stable 338 
in plasma at -20°C after 8 months of storage and over 3 freeze-thaw cycles. Standard working 339 
solutions of SRA737 and IS, prepared in DMF and stored at -20°C, were stable for at least 2 340 
months. Table 3 provides a summary of the stability data generated as part of the assay 341 
validation. In addition to these stability experiments formalised in the method validation plan, 342 
experiments were also carried out to investigate the impact of storing whole blood samples 343 
from patients who have received SRA737, for defined time periods ahead of plasma 344 
separation and storage. Results indicated that storage of whole blood samples for 8 h or 24 h 345 
at either room temperature or 4°C had no effect on the concentration of SRA737 determined 346 
in plasma, with mean values varying <5% from data obtained when whole blood samples were 347 
centrifuged immediately following collection.  348 
 349 
Clinical sample analysis 350 
Analysis of plasma samples obtained from a patient receiving a single oral dose of 40 mg 351 
SRA737 indicated that the assay could successfully be utilised to quantify SRA737 in clinical 352 
trial samples. Figure 3D shows an SRM chromatogram obtained from an extracted plasma 353 
sample collected from a patient receiving SRA737 and Figure 4 shows the plasma 354 
concentration-versus-time curve for SRA737 at a dose of 40 mg. Quantifiable drug levels were 355 
measured over a 24h period following drug administration, with a Cmax of 95 ng/mL observed 356 
at a Tmax of 1 h.   357 
 358 
  359 
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Conclusions & future perspective 360 
The bioanalytical method described has been validated for the quantitative measurement of 361 
the CHK1 inhibitor SRA737 in human plasma obtained from patients currently participating in 362 
early phase clinical trials with this promising drug candidate. The method utilises small plasma 363 
volumes, is rapid, highly sensitive, precise and accurate. The observed limit of quantification 364 
clearly facilitates the determination of SRA737 concentrations in clinical samples, even at low 365 
doses administered during the early patient cohorts recruited to the ongoing clinical trials.  366 
 367 
Experiments to investigate the interference of potentially co-administered drugs were not 368 
carried out as part of the assay method validation as it was felt that it was unlikely that co-369 
administered drugs with contrasting chemical structures would interfere with the assay and 370 
due to the number of potentially co-administered drugs being prescribed in late stage cancer 371 
patients participating in a phase I clinical trial. However, further experiments to investigate 372 
potential interactions with specific co-administered anticancer drugs may be warranted for 373 
future drug combination studies. It should also be highlighted that as SRA737 is at an early 374 
stage of clinical development, incurred sample reanalysis experiments have not yet been 375 
carried out. The FDA guidance and EMEA guideline on Bioanalytical method validation 376 
stipulate that 7-10% of the samples should be analysed around the Cmax and in the 377 
elimination phase. Further information will be gathered on these aspects prior to initiating 378 
incurred sample reanalysis studies. 379 
 380 
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The assay is now being utilised to generate novel data concerning the pharmacokinetics of 381 
SRA737, facilitating investigations into the importance of systemic drug exposure to this agent 382 
in determining clinical response and toxicity in cancer patients. 383 
  384 
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Executive Summary 385 
Background 386 
• a HPLC-MS/MS method was developed to quantify the novel anticancer drug SRA737 in 387 
human plasma obtained from patients participating in an early phase clinical trial. 388 
Experimental 389 
• The method utilises small samples volumes (20µL), involving protein precipitation with 390 
acetonitrile and use of 13C15N deuterated SRA737 as internal standard. 391 
Results and discussion 392 
 • A rapid and selective assay was developed according to EMA and FDA guidelines for 393 
bioanalytical method validation, covering a range of 5-20,000 ng/mL as appropriate for the 394 
analysis of drug levels in patient samples. 395 
 • The method is being utilised successfully to quantify SRA737 in clinical samples obtained 396 
from patients participating in an ongoing phase I trial. 397 
  398 
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TABLES 427 
Table 1. Inter-day linearity, accuracy and precision of calibration curves of SRA737 in human plasma 428 
 429 
 SRA737 plasma concentrations (ng/mL) 
Day 5.0 10.0 20.0 50.0 100 500 1000 5000 10000 20000 
1 4.9 10.5 19.7 51.7 99 547 988 5049 9794 18865 
2 5.2 9.8 18.5 51.6 103 509 1068 5174 9300 20160 
3 4.9 10.1 19.9 51.6 104 554 1030 5158 9302 18018 
4 5.0 9.7 21.6 51.9 101 532 1023 4933 9900 18085 
5 5.0 9.7 20.6 51.9 107 485 998 5367 10053 18116 
6 5.0 10.0 19.1 53.5 102 491 979 5504 9143 20633 
7 5.0 9.9 19.8 48.9 105 515 1037 5414 9286 19504 
Mean (n=4) 5.0 10.0 19.9 52 103 519 1018 5229 9540 19054 
SD 0.1 0.3 1.0 1.4 2.6 26.6 31.2 207.0 363.7 1068.4 
Accuracy (%) 100.1 99.7 99.4 103.2 103.1 103.8 101.8 104.6 95.4 95.3 
Precision (%) 1.8 2.9 5.1 2.7 2.5 5.1 3.1 4.0 3.8 5.6 
 
SD: Standard deviation  
 430 
 431 
 432 
 433 
434 
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Table 2. Intra/Inter-day precision and accuracy of the method for the analysis of SRA737 in human 435 
plasma (LLOQ, LQC, MQC and HQC) 436 
 437 
Sample Day SRA737 
concentration 
(ng/mL) 
Accuracy 
(%) 
Precision 
(%) 
SRA737 
concentration 
(ng/mL) 
Accuracy 
(%) 
Precision 
(%) 
RE (%) 
  Mean SD   Mean SD    
LLOQ 1 5.46 0.15 109.2 3.27      
 2 5.02 0.13 100.4 2.89      
 3 5.04 0.27 100.8 5.02      
 4 5.06 0.30 101.2 6.03      
 1-4     5.15 0.28 102.9 5.4 -2.9 
           
LQC 1 30.6 2.08 102 6.80      
 2 31.7 2.49 106 7.87      
 3 29.3 0.57 97.5 1.94      
 4 31.2 2.21 104 7.06      
 1-4     30.7 1.05 102 3.41 2.33 
           
MQC 1 2933 104 97.8 3.55      
 2 3020 113 101 3.73      
 3 2896 161 96.5 5.57      
 4 3033 92.9 101 3.06      
 1-4     2971 66.7 99.0 2.24 -0.98 
           
HQC 1 15000 700 100 4.67      
 2 15300 436 102 2.85      
 3 15040 577 100 3.84      
 4 15500 100 103 0.65      
 1-4     15210 235 101 1.54 1.40 
 438 
NA: Not applicable; SD: Standard Deviation; RE: Relative Error 439 
  440 
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Table 3. Short and long-term stability data for SRA737 in various different matrices 441 
 442 
Temp Matrix Time LQC results from 3 replicates HQC results from 3 replicates 
Mean SD Accuracy 
(%) 
CV 
(%) 
Mean SD Accuracy 
(%) 
CV 
(%) 
RT plasma 4 hrs 29.3 1.11 97.7 3.80 14500 557 96.7 3.84 
4°C plasma 7 days 30.8 3.50 103 11.4 13967 115 93.1 0.83 
4°C MP 7 days 30.6 1.89 102 6.17 15400 265 103 1.72 
-20°C plasma 1 FTC 29.2 1.37 97.2 4.68 15967 874 106 5.47 
-20°C plasma 2 FTC 29.8 2.31 99.4 7.74 14700 700 98.0 4.76 
-20°C plasma 3 FTC 29.7 0.68 98.9 2.29 15333 473 102 3.08 
-20°C DMF 2 months 31.0 1.07 103 3.45 14800 436 98.7 2.95 
-20°C plasma 2 months 29.5 2.11 98.4 7.14 14550 495 97.0 3.40 
-20°C plasma 8 months 29.2 4.03 97.3 13.8 14233 1101 94.9 7.74 
 443 
RT: Room temperature; MP: Mobile phase; FTC: Freeze thaw cycle; DMF: Dimethylformamide 444 
 445 
 446 
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Figure Legends 448 
 449 
Figure 1. Chemical structures of (A) SRA737 (Molecular Weight: 379.34) and (B) labelled 450 
SRA737 ([13C15N] deuterated SRA737) (Molecular Weight: 383.35)  451 
 452 
Figure 2. MS and MS/MS mass spectra of (A) SRA737 and (B) IS ([13C15N] deuterated SRA737). 453 
 454 
Figure 3. (A) SRM chromatograms of a human blank plasma sample (volume of injection 3 µl); 455 
(B) SRM chromatograms of a human blank plasma sample with IS (volume of injection 3 µl); 456 
(C) signal-to-noise ratio of SRA737 at the LLOQ (volume of injection 10 µl); (D) SRM 457 
chromatograms showing SRA737 and the IS of a plasma sample collected from a patient 458 
receiving a single oral dose of 40mg SRA737 (volume of injection 3 µl). 459 
 460 
Figure 4. Plasma concentration-versus-time profile of SRA737 in a patient following a single 461 
oral administration of 40mg SRA737. 462 
  463 
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Figure 1  464 
 465 
 466 
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Figure 2 470 
 471 
 472 
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Figure 3 476 
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Figure 4 481 
 482 
 483 
